While Ozempic’s weight loss benefits are widely touted, the conversation is increasingly shifting toward its side effects. Commonly reported issues include: nausea, constipation and “Ozempic face,” a condition where rapid weight loss leads to a gaunt appearance.

What health experts think of the growing Ozempic “microdosing” trend that claims taking very small doses of GLP-1 drugs can still help people lose weight with fewer side effects at a lower cost.

The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper versions. After an outcry, it’s reconsidering.

According to a report, Ozempic is not approved for weight loss, but some physicians prescribe it to be used for weight loss. “Ozempic® is not FDA approved for weight loss or chronic weight management,” the Ozempic website says.

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

FDA approval: Ozempic is FDA-approved for Type 2 diabetes, while Wegovy is FDA-approved for weight loss. Cost: Ozempic is typically more affordable than Wegovy. At the time of publishing, the list price for Ozempic was $968.52 per month, whereas the list price for Wegovy was $1,349.02 per month. List prices are the price set by the manufacturer.

Weight loss drugs have risen in popularity in the recent years, but a disconnect remains between those who need the drugs and those who can afford to buy them. Drugs like Ozempic, which isn’t available in New Zealand,